Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

NCT02743013 | Completed Phase 1

• 2 other identifiers: CCD-05993BA1-012015-005198-19
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical pharmacology study is performed to evaluate the total systemic exposure and the lung availability of CHF 5993 DPI and pMDI with and without valved holding chamber, in healthy volunteers.

Conditions

COPD

Outcome Measures

Primary Outcomes (4)

• Evaluation of the area under the curve (AUC0-t) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.

  AUC0-t

  72 hours after adminstration

• Evaluation of the Area under the curve (AUC) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.

  AUC 0-t

  72 hours after adminstration

• Evaluation of the Maximum Plasma Concentration (Cmax) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.

  Cmax

  72 hours after adminstration

• Evaluation of the Maximum Plasma Concentration (Cmax) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.

  Cmax

  72 hours after adminstration

Secondary Outcomes (5)

• Evaluate the Area Under the Curve of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage

  72 hours after adminstration

• Evaluate the Maximum Plasma Concentration of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage

  72 hours after adminstration

• Evaluate the number of Adverse events and adverse drug reactions

  72 hours after adminstration

• Evaluation of Blood pressure

  72 hours after adminstration

• Evaluation of the heart rate

  72 hours after adminstration

Study Arms (5)

CHF 5993 100/6/12,5 pMDI

ACTIVE COMPARATOR

with/without Charcoal Block

Drug: CHF 5993 100/6/12,5 pMDI

CHF 5993 100/6/12,5 pMDI (replicate)

ACTIVE COMPARATOR

with/without Charcoal Block

Drug: CHF 5993 100/6/12,5 pMDI replicate

CHF 5993 100/6/12,5 pMDI VHC

ACTIVE COMPARATOR

with/without Charcoal Block with Valved Holding Chamber

Drug: CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber

CHF 5993 100/6/12,5 DPI test 1

EXPERIMENTAL

with/without Charcoal Block

Drug: CHF 5993 100/6/12,5 DPI Test 1

CHF 5993 100/6/12,5 DPI test 2

EXPERIMENTAL

with/without Charcoal Block

Drug: CHF 5993 100/6/12,5 DPI Test 2

Interventions

CHF 5993 100/6/12,5 pMDI DRUG

CHF 5993 100/6/12,5 pMDI

CHF 5993 100/6/12,5 DPI Test 1 DRUG

CHF 5993 100/6/12,5 DPI test 1

CHF 5993 100/6/12,5 DPI Test 2 DRUG

CHF 5993 100/6/12,5 DPI test 2

CHF 5993 100/6/12,5 pMDI replicate DRUG

CHF 5993 100/6/12,5 pMDI (replicate)

CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber DRUG

CHF 5993 100/6/12,5 pMDI VHC

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject's written informed consent obtained prior to any study related procedure.
• Ability to understand the study procedures, the risks involved, and ability to be trained to use the pMDI device correctly with AIM™ (Aerosol Inhalation Monitor) Vitalograph®.
• Ability to generate sufficient PIF (at least 40 L/min) using the In-Check device simulating NEXThaler® device.
• Male and female Caucasian subjects aged 18 to 55 years inclusive.
• Body mass index (BMI) within the range of 18 to 30 kg/m2 inclusive.
• Non-smokers or ex-smokers who smoked \< 5 pack years (pack-years = the number of cigarette packs per day, times the number of years) and stopped smoking \> 1 year prior to screening.
• Good physical and mental status, determined on the basis of the medical history and a general clinical examination, at screening and before randomization.
• Lung function measurements within normal limits (Normal values: FEV1/FVC is \> 0.70 and FEV1 \> 80% predicted).
• Female subject of non-childbearing potential (WONCBP) defined as physiologically incapable of becoming pregnant (i.e. post-menopausal or permanently sterile) and female subjects of childbearing potential (WOCBP) fulfilling one of the following criteria:
• WOCBP with fertile male partners: they and/or their partner of childbearing potential must be willing to use a double barrier contraceptive method including one highly effective birth control method and one acceptable birth control method (male or female condom with or without spermicide and/or cap, diaphragm or sponge with spermicide), from the signature of the informed consent and until 3 months after follow-up visit;
• WOCBP with non-fertile male partners: contraception is not required in this case.

You may not qualify if:

• Blood donation (equal or more than 450 ml) or blood loss, less than 8 weeks prior screening or prior randomization.
• Abnormal haemoglobin level defined as \< 10.5 g/dl
• For females only: pregnant and lactating female subjects, confirmed by a positive serum test at screening and/or urine test before randomization.
• Positive HIV1 or HIV2 serology.
• Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C.
• Unsuitable veins for repeated venipuncture.
• Documented history of alcohol abuse within 12 months prior to screening.
• Documented history of drug abuse within 12 months prior to screening, or positive urine drug test performed at screening and/or before randomization.
• Subjects who have a positive urine test for cotinine at screening and/or before randomization.
• Clinically relevant abnormal laboratory values, suggesting an unknown disease and requiring further clinical investigation.
• Clinically relevant and uncontrolled respiratory, cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol.
• Subjects with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic.
• Subjects with history of asthma, including childhood asthma.
• Known intolerance/ hypersensitivity to any of the excipients contained in any of the formulations used in the trial.
• Abnormal 12-lead digitized Electrocardiogram (12-lead ECG) parameter (i.e.: QRS \> 120 msec and/or PR \> 220 msec and/or HR \< 40 bpm and/or HR \> 110 bpm and/or QTcF \> 450 ms for males or QTcF \> 470 ms for female, considering the average from triplicate) or 12-lead ECG evaluated as abnormal clinical significant by the investigator, at screening.

Sponsors & Collaborators

• Chiesi Farmaceutici S.p.A.: lead

Study Sites (1)

SGS CPU Antwerpen

Antwerp, Belgium

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Inhalation Spacers

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Metered Dose Inhalers; Nebulizers and Vaporizers; Equipment and Supplies

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 31, 2016
• First Posted: April 19, 2016
• Study Start: April 1, 2016
• Primary Completion: July 1, 2016
• Study Completion: July 1, 2016
• Last Updated: July 2, 2021

Record last verified: 2021-06

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)